{
  "statements": [
    {
      "id": "fda_poda.statement:1",
      "description": "Treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation",
      "extensions": [
        {
          "name": "additional_description",
          "value": "Tablets and oral suspension"
        },
        {
          "name": "original_or_supplemental_approval",
          "value": "original"
        },
        {
          "name": "clinical_trial_ids",
          "value": ["NCT04775485"]
        },
        {
          "name": "original_spreadsheet_rows",
          "value": [
            "Tovorafenib [Ojemda],kinase inhibitor,\"BRAF, CRAF\",\"Treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation\",6 months and older,2024-04-23,Original,NCT04775485,Tablets and oral suspension,"
          ]
        }
      ],
      "specifiedBy": {
        "id": "fda_poda.method:1",
        "type": "Method",
        "name": "Federal Drug Administration Development & Approval Process for Drugs",
        "reportedIn": {
          "type": "Document",
          "name": "Development & Approval Process | Drugs",
          "title": "Development & Approval Process | Drugs",
          "documentType": "webpage",
          "urls": [
            "https://www.fda.gov/drugs/development-approval-process-drugs"
          ]
        }
      },
      "reportedIn": {
        "type": "Document",
        "urls": [
          "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric"
        ]
      },
      "type": "Statement",
      "proposition": {
        "subjectVariant": {
          "id": "fda_poda.variant:BRAF V600E",
          "type": "CategoricalVariant",
          "name": "BRAF V600E"
        },
        "objectTherapeutic": {
          "name": "Tovorafenib",
          "conceptType": "Therapy",
          "id": "drugsatfda.nda:217700",
          "extensions": [
            {
              "name": "trade_names",
              "value": ["Ojemda"]
            },
            {
              "name": "drug_class",
              "value": "kinase inhibitor"
            }
          ]
        },
        "geneContextQualifier": {
          "conceptType": "Gene",
          "id": "fda_poda.gene:BRAF",
          "name": "BRAF"
        },
        "conditionQualifier": {
          "conditions": [
            {
              "id": "fda_poda.condition:low-grade glioma",
              "name": "low-grade glioma",
              "conceptType": "Condition",
              "extensions": [
                {
                  "name": "aliases",
                  "value": ["LGG"]
                }
              ]
            },
            {
              "id": "fda_poda.onset:6 months of age and older",
              "name": "6 months of age and older",
              "conceptType": "Condition"
            }
          ],
          "membershipOperator": "AND"
        }
      },
      "direction": "supports",
      "strength": {
        "primaryCoding": {
          "system": "https://www.fda.gov",
          "code": "FDA-Approved"
        },
        "mappings": [
          {
            "coding": {
              "name": "FDA recognized evidence",
              "system": "https://go.osu.edu/evidence-codes",
              "code": "e000002"
            },
            "relation": "exactMatch"
          }
        ]
      }
    }
  ]
}
